Reata Pharmaceuticals, Inc. Announces Requested Withdrawal Of Registration Statement Due To Adverse Market Conditions
Published: Dec 12, 2016
IRVING, Texas, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata”), a clinical-stage biopharmaceutical company, today announced that, due to adverse market conditions, it has requested withdrawal of its Registration Statement on Form S-1 (File No. 333-214915) (the “Registration Statement”) that was filed on December 6, 2016, with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed underwritten public offering of shares of its Class A common stock. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in regulating cellular metabolism and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-?B, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Contact: Reata Pharmaceuticals, Inc. (972) 865-2219 email@example.com Investor Relations: The Trout Group Lee M. Stern, CFA (646) 378-2922 IR@reatapharma.com